F
Franco Maggiolo
Researcher at University of Milan
Publications - 175
Citations - 5445
Franco Maggiolo is an academic researcher from University of Milan. The author has contributed to research in topics: Emtricitabine & Regimen. The author has an hindex of 34, co-authored 159 publications receiving 4779 citations.
Papers
More filters
Journal ArticleDOI
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Sharon Walmsley,Antonio Antela,Nathan Clumeck,Dan Duiculescu,Andrea Eberhard,Felix Gutieŕrez,Laurent Hocqueloux,Franco Maggiolo,Uriel Sandkovsky,Catherine Granier,Keith A. Pappa,Brian Wynne,Sherene Min,Garrett Nichols +13 more
TL;DR: Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine, thus meeting the criterion for superiority.
Journal ArticleDOI
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
Antonella Castagna,Franco Maggiolo,Giovanni Penco,David Wright,Anthony Mills,Robert M. Grossberg,Jean-Michel Molina,Julie Chas,J. Durant,Santiago Moreno,Manuela Doroana,Mounir Ait-Khaled,Jenny Huang,Sherene Min,Ivy Song,Cindy Vavro,Garrett Nichols,Jane M. Yeo +17 more
TL;DR: DTG 50 mg BID–based therapy was effective in this highly treatment-experienced population with INI-resistant virus, and a strong association between baseline DTG susceptibility and response was demonstrated.
Journal ArticleDOI
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen,Franco Maggiolo,Jose R. Arribas,A Rakhmanova,Patrick Yeni,Benjamin Young,Jürgen K. Rockstroh,Steve Almond,Ivy Song,Sherene Min +9 more
TL;DR: Dolutegravir was effective when given once daily without a pharmacokinetic booster and was well tolerated at all assessed doses, and support the assessment of once daily 50 mg doluteg Gravir in phase 3 trials is supported.
Journal ArticleDOI
Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors
Franco Maggiolo,Laura Ravasio,Diego Ripamonti,Giampietro Gregis,Giampaolo Quinzan,Claudio Arici,Monica Airoldi,Fredy Suter +7 more
TL;DR: Patients receiving NNRTIs report a higher rate of adherence than do patients receiving PIs, and the number of pills and daily doses received correlated with the reported adherence rate.
Journal ArticleDOI
One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects
Monica Airoldi,Mauro Zaccarelli,Luca Bisi,Teresa Bini,Andrea Antinori,Cristina Mussini,Francesca Bai,Giancarlo Orofino,Laura Sighinolfi,Andrea Gori,Fredy Suter,Franco Maggiolo +11 more
TL;DR: By substituting a one-pill once-a-day HAART for HIV-infected patients on highly active antiretroviral therapy (HAART), an improvement of both adherence and QoL is observed while maintaining high virologic and immunologic efficacy.